Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children

Transplantation Clinical Trial

— COVAGREF  

Official title:

Vaccines Immunogenicity in Children Transplanted or Candidate for a Renal, Hepatic, Cardiac or Pulmonary Transplantation, Followed in the Rhône-Alpes Region. A Descriptive and Prospective Monocentric Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03180359
• Other study ID #: 69HCL17_0354
• Secondary ID: 2015-A00854-45
• Status: Completed
• Phase: N/A
• Start date: January 1, 2016
• Est. completion date: October 13, 2019

Study information

• Verified date: March 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Thanks to improved surgical techniques, postoperative management and immunosuppressive therapies, an increasing number of children benefit from renal, hepatic, cardiac and pulmonary transplantation. Infection is a significant cause of mortality and morbidity in these patients, particularly due to vaccine-preventable diseases. Vaccination is one of the effective means of reducing infection-related mortality in these particularly vulnerable children. It is mostly well-tolerated, but all the more effective as it is performed early before transplantation, at best during a dedicated consultation, according to a vaccine scheme adapted to the immunocompromised child. In the almost constant absence of clinical efficacy data in populations of immunocompromised individuals, vaccine efficacy is most often indirectly estimated by immunogenicity, using protective correlates obtained by extrapolation in immunocompetent individuals. Primary objective: To estimate the immunogenicity of vaccines recommended in children transplanted or candidate for renal, hepatic, cardiac and pulmonary transplantation, using serological titers measurements before and after a vaccine injection for: influenza, pneumococcus, chicken pox, measles, tetanus, hepatitis A and hepatitis B. These serological titers will be compared to correlates of protection existing for each valency. The evolution of serological titers will be described during the first year. The vaccination will be carried out within the routine care, according to the recommendations. Secondary objectives: - describe and quantify the vaccination status of patients - describe the vaccination coverage of their entourage - evaluate the tolerance and efficacy of vaccines

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: October 13, 2019
• Est. primary completion date: October 13, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 17 Years

Eligibility

Inclusion Criteria:

• children and adolescent between 0 and 17 years old
• registered in the database of the Agency of Biomedicine
• transplanted or waiting for a renal, hepatic, cardiac or pulmonary transplantation
• followed up in the Rhône-Alpes region between January 1st , 2015 and December 31th, 2016
• patients requiring vaccination in standard care

Exclusion Criteria:

• adults
• children or adolescent not able not comply with protocol
• children, adolescent or patient parents or legal guardian not opposed to study participation

Related Conditions & MeSH terms

• Transplantation

Intervention

Biological:
• Recommended vaccine scheme according to French Vaccine Schedule 2015
BCG Measles mumps rubella (MMR) Varicella (chicken pox) Rotavirus Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable) Yellow Fever Diphteria tetanus poliomyelitis whopping cough (DTwP) Haemophilus influenzae type b Hepatitis B Meningococcus conjugate Pneumococcus Human papillomavirus Hepatitis A Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity of vaccines recommended in children transplanted or candidate for renal, hepatic, cardiac and pulmonary transplantation	The immunogenicity is appraised from serological titer before and after vaccine injection. These serological titers will be compared to existing reference protection correlates for each valency, and defined as protective or non-protective: Tetanus (>0,1 UI/ml), hepatitis B (>10 mUI/ml), hepatitis A (> 20 mUI/ml), measles (0,18 in EIA index), chicken pox (> 5 gp Elisa UI/ml or > 50 UI/l with an highly sensitive test), influenza (Hemagglutination Inhibition Assay > 1/40), pneumococcus (0,35 µg/ml, > 0,4 mg/l for each specific serotype, if > 2/3 or 4/6, protecting serotype)	at Month 0
Primary	Immunogenicity of vaccines recommended in children transplanted or candidate for renal, hepatic, cardiac and pulmonary transplantation	The immunogenicity is appraised from serological titer before and after vaccine injection. These serological titers will be compared to existing reference protection correlates for each valency, and defined as protective or non-protective: Tetanus (>0,1 UI/ml), hepatitis B (>10 mUI/ml), hepatitis A (> 20 mUI/ml), measles (0,18 in EIA index), chicken pox (> 5 gp Elisa UI/ml or > 50 UI/l with an highly sensitive test), influenza (Hemagglutination Inhibition Assay > 1/40), pneumococcus (0,35 µg/ml, > 0,4 mg/l for each specific serotype, if > 2/3 or 4/6, protecting serotype)	between Month 1 and Month 3
Primary	Immunogenicity of vaccines recommended in children transplanted or candidate for renal, hepatic, cardiac and pulmonary transplantation	The immunogenicity is appraised from serological titer before and after vaccine injection. These serological titers will be compared to existing reference protection correlates for each valency, and defined as protective or non-protective: Tetanus (>0,1 UI/ml), hepatitis B (>10 mUI/ml), hepatitis A (> 20 mUI/ml), measles (0,18 in EIA index), chicken pox (> 5 gp Elisa UI/ml or > 50 UI/l with an highly sensitive test), influenza (Hemagglutination Inhibition Assay > 1/40), pneumococcus (0,35 µg/ml, > 0,4 mg/l for each specific serotype, if > 2/3 or 4/6, protecting serotype)	Month 12
Primary	Immunogenicity of vaccines recommended in children transplanted or candidate for renal, hepatic, cardiac and pulmonary transplantation	The immunogenicity is appraised from serological titer before and after vaccine injection. These serological titers will be compared to existing reference protection correlates for each valency, and defined as protective or non-protective: Tetanus (>0,1 UI/ml), hepatitis B (>10 mUI/ml), hepatitis A (> 20 mUI/ml), measles (0,18 in EIA index), chicken pox (> 5 gp Elisa UI/ml or > 50 UI/l with an highly sensitive test), influenza (Hemagglutination Inhibition Assay > 1/40), pneumococcus (0,35 µg/ml, > 0,4 mg/l for each specific serotype, if > 2/3 or 4/6, protecting serotype)	3-month post-transplantation (if transplantation occurs during the study)
Secondary	Levels of blood antibodies corresponding to the following vaccine valencies: influenza, pneumococcus, chicken pox (varicella), measles, tetanus, hepatitis A and hepatitis B.		at Month 0
Secondary	Levels of blood antibodies corresponding to the following vaccine valencies: influenza, pneumococcus, chicken pox (varicella), measles, tetanus, hepatitis A and hepatitis B.		between Month 1 and Month 3
Secondary	Levels of blood antibodies corresponding to the following vaccine valencies: influenza, pneumococcus, chicken pox (varicella), measles, tetanus, hepatitis A and hepatitis B.		at Month 12
Secondary	Levels of blood antibodies corresponding to the following vaccine valencies: influenza, pneumococcus, chicken pox (varicella), measles, tetanus, hepatitis A and hepatitis B.		3-month post-transplantation (if transplantation occurs during the study)
Secondary	the number of early or late injections	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	at Month 0,
Secondary	the number of missing injections and supplementary injections	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	at Month 0,
Secondary	the number of days in advance or delayed from recommended injections (per injection and cumulative)	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	at Month 0,
Secondary	the number of early or late injections	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	between Month 1 and Month 3
Secondary	the number of missing injections and supplementary injections	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	between Month 1 and Month 3
Secondary	the number of days in advance or delayed from recommended injections (per injection and cumulative)	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	between Month 1 and Month 3
Secondary	the number of early or late injections	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	at Month 12
Secondary	the number of missing injections and supplementary injections	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	at Month 12
Secondary	the number of days in advance or delayed from recommended injections (per injection and cumulative)	Vaccine status compliance with vaccine recommendation, from literature data and from the opinion of the Vaccine Technical Committee President.; Compliance will be appraised by considering for each valence: the number of early or late injections; the number of missing injections and supplementary injections; the number of days in advance or delayed from recommended injections (per injection and cumulative) 2 age groups will be differentiate : <2 years (primary vaccination) and >2 years For each age group, early or late injections are defined by considering literature data and the opinion of the Vaccine Technical Committee President.	at Month 12
Secondary	Vaccination coverage of patients' entourage	Number of missing, additional, early or late injections, compared to vaccine recommendations.	at month 0
Secondary	Patients' vaccine tolerance	Local reactions, fever, clinical or biological signs of rejection	at Week 1
Secondary	Patients' vaccine tolerance	Local reactions, fever, clinical or biological signs of rejection	at Month 1 after injection